There was a seemingly paradoxical moment towards the end of Paratek Pharmaceuticals Inc.’s omadacycline US FDA advisory committee meeting that exemplifies how many stakeholders feel about new antibiotics: They encourage their development, but aren't exactly enthusiastic about their use.
The Antimicrobial Drugs Advisory Committee had voted overwhelmingly to support approval of two indications at the Aug. 8 meeting: acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). (